Plasma bile acid profile in patients with and without type 2 diabetes
The 1.2-1.6 g/kg/day target means protein needs to account for 16-24% of total energy intake
That we need
Cardiovascular outcomes trials such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown that certain GLP-1 receptor agonists significantly reduce major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
PlexusDx conducts thorough medical history review, asks about pancreatitis, gallbladder disease, thyroid cancer, kidney function, and retinal disease before dispensing any compounded medication from licensed 503A pharmacies
In fact, one recent propensity-matched analysis of non-diabetic patients found that GLP-1 use was associated with a lower incidence of UTI, 8.8% compared to 13.3% in the control group